Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives

Table 3 Comparison of response and median survival after transarterial radioembolization and transarterial chemoembolization from recent studies (modified from Lau et al[93])

Ref.	Treatment	n	OS (mo)	TTP (mo)	Response (CP/PR) %WHO/RECIST criteria	RR (CP/PR) %EASL criteria	Downstaged/LT %	Mean days in hospitalper treatment
Lewandowski et al[69]	TARE (TheraSphere1)	43	35.7	33.3	61	86	58a	0a
	TACE	43	18.7	18.2	37	71	31	3
Kooby et al[88]	TARE (SIR-Spheres2)	27	6	NR	11	NR	NR	1.7a
	TACE	44	6		6			6
Carr et al[68]	TARE (TheraSphere1)	99	11.5	NR	41	NR	NR	NR
	TACE	691	8.5		60
Salem et al[63]	TARE (TheraSphere1)	123	20.5	13.3	49	72	25	0a
	TACE	122	17.4	8.4	46	69	36	1.8

¹BTG International Canada Inc., Ottawa, Ontario, Canada;

²Sirtex Medical, North Sydney, Australia.

^aP < 0.05, response and median survival after transarterial radioembolization vs transarterial chemoembolization. OS: Overall survival; TTP: Time to tumor progression; CP: Complete response; PR: Partial response; RR: Response rate; WHO: World Health Organization; RECIST: Response Evaluation Criteria in solid tumors; TARE: Transarterial radioembolization; TACE: Transarterial chemoembolization; EASL: European Association for the Study of the Liver; LT: Liver transplantation; NR: Not reported.